Antibodies targeting XCL1 and methods of using the same
Antibodies targeting XCL1 and XCL2 address the inadequacies of current treatments by effectively neutralizing these chemokines, thereby managing autoimmune and inflammatory diseases.
Patent Information
- Application Number
- JP2024084764
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-24
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for autoimmune and chronic inflammatory diseases, such as alopecia areata, vitiligo, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, and psoriasis, are inadequate for a significant portion of patients, and there is a need for therapies targeting human XCL1 and XCL2 to manage these conditions effectively.
Development of antibodies that specifically bind and neutralize human XCL1 and XCL2, with high affinity and low immunogenicity, capable of inhibiting the chemokines' activity and reducing their interaction with glycosaminoglycans on cell surfaces.
The antibodies effectively neutralize XCL1 and XCL2, inhibiting CD8+ T cell migration and reducing inflammation, providing therapeutic benefits for immune-mediated diseases.
Smart Images

Figure 2024169416000001 
Figure 2024169416000002 
Figure 2024169416000003
Abstract
Description
[Technical field]
[0001] (Sequence listing file) This application has been submitted with a sequence listing in ST.26 XML format. The sequence listing is provided as a file entitled "30574_SequenceListing", created on May 6, 2024, and is 43 kilobytes in size. The sequence listing information in ST.26 XML format is incorporated herein by reference in its entirety.
[0002] FIELD OF THEINVENTION The present invention is in the field of medicine. More specifically, the present invention relates to antibodies against lymphotactins, particularly human chemokines XCL1 and XCL2, pharmaceutical compositions containing such antibodies, and methods of using such antibodies. The antibodies disclosed herein bind to and neutralize XCL1 and XCL2. The antibodies and methods of the present invention are expected to be useful in the field of autoimmune and chronic inflammatory diseases (collectively referred to herein as immune-mediated diseases), particularly in the field of diseases such as alopecia areata, vitiligo, ulcerative colitis (UC), rheumatoid arthritis (RA), multiple sclerosis (MS), type 1 diabetes, psoriasis, asthma, including their treatment. [Background technology]
[0003] XCL1 and XCL2, also known as lymphotactin-α and -β, respectively, are the only members of the C chemokine / γ chemokine family. XCL1 is expressed and secreted by a variety of immune cells, including activated CD8+ T cells, CD4+ T cells, natural killer (NK) cells, thymic medullary epithelial cells, etc. XCL2 is a paralogue of XCL1 and is believed to have arisen from gene duplication, with a nearly identical amino acid sequence to XCL1 (only two amino acids in the N-terminal region differ from XCL1). XCL1 and XCL2 are believed to have similar functions as a result of this structural similarity.
[0004] Unlike most other chemokines, which have four cysteine residues near their amino termini that can form two disulfide bonds, XCL1 and XCL2 have only two such cysteines that form a single disulfide bond. This allows the chemokines to interconvert and denature between a first conformation with a standard monomeric α-helical chemokine fold and a second, predominantly β-sheet form. This conversion between forms typically occurs several times per second. The monomeric α-helical form can bind and activate the receptor XCR1, inducing cell migration. The α-helical form undergoes a conformational change to a β-sheet form, which can exist in a monomeric form but favors dimerization. When in the dimer or β-sheet conformation, XCL1 is inactive for XCR1 binding and the dimer can attach to glycosaminoglycans (GAGs) on the cell surface. The monomeric α-helical form does not bind to GAGs. See Lei and Takahama, Microbes and Infection 14(2012)262-267; Fox et al., ACS Chem.Biol.10(11)(2015)2580-2588. The frequent conversion between these forms complicates the design of anti-XCL1 and anti-XCL2 antibodies, especially as therapeutic agents, since antibodies capable of binding to the dimeric form of the chemokine may bind primarily to the inactive form of the chemokine, resulting in unknown properties in terms of pharmacokinetics, immunogenicity, and efficacy, especially considering the inactivity of the dimeric and β-sheet forms and their tendency to aggregate at the cell surface on GAGs.
[0005] Autoimmune diseases are a form of immune-mediated disease that arise from the body producing an immune response against its own tissues. These conditions are often chronic and can be debilitating, even fatal. Current FDA-approved treatments for immune-mediated diseases include corticosteroids, which are often used to treat acute inflammation, as well as biologics that target TNFα, interleukin-12, -17, and -23. Although these treatments have been proven effective in reducing symptoms in some patients, a percentage of patients remain unresponsive or lose response to currently available treatments. Thus, there remains a need for additional therapies that target different human targets and pathways for the treatment of immune-mediated diseases.
[0006] Some autoimmune diseases, including alopecia areata, vitiligo, UC, type 1 diabetes, psoriasis, RA, MS, and asthma, are associated with hyperactivity of CD8+ T cells and tissue damage by CD8+ T cells when these cells migrate to certain sites in the body, but many of the details regarding the mechanisms of CD8+ T cell activation underlying these conditions remain to be elucidated. For example, the specific role of dendritic cells (DCs) in CD8+ T cell activation has been generally elucidated in the field of oncology rather than immunology, such as in the study of checkpoint antagonists. This is true for a subset of DCs known as conventional dendritic cell 1 (cDC1), see, for example, Bowman-Kirigin et al., "The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain," Cancer Immunol Res, 11(1)(2023) p.20-37.
[0007] Although XCL1 antibodies exist as research tools for the detection and visualization of XCL1, to date there are no approved or known clinical candidates for XCL1-specific antagonist antibody therapy. Thus, there remains an unmet need for antibodies, pharmaceutical compositions, and methods targeting human XCL1 that are useful for the treatment of immune-mediated diseases such as RA, MS, asthma, psoriasis, UC, type 1 diabetes, alopecia areata, and vitiligo. There is a need for XCL1 antibodies that possess good therapeutic characteristics, including being potent neutralizers (i.e., antagonists) of human XCL1. Advantageous properties of such antibodies may include high binding affinity to human XCL1, as well as low non-specific binding, particularly to other chemokines that may have similar sequences and / or structures as XCL1. Such XCL1 antibodies should also possess a therapeutically acceptable pharmacokinetics (Pk) profile and demonstrate low immunogenicity. Such XCL1 antibodies should also be amenable to commercial manufacture, including high levels of solubility and low levels of aggregation. The present disclosure provides XCL1 antibodies that address one or more of these needs, for use in treating immune-mediated diseases.
[0008] Thus, in certain embodiments, the present invention provides antibodies against human XCL1. The antibodies disclosed herein also bind to and neutralize human XCL2. Summary of the Invention
[0009] According to some embodiments, the antibodies of the invention are antagonistic to human XCL1, and in some embodiments, to human XCL2. In one aspect, described herein is an antibody that binds to human XCL1 comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR). The HCVR comprises complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3. The LCVR comprises CDRs LCDR1, LCDR2, and LCDR3. HCDR1 is or comprises SEQ ID NO: 10. HCDR2 is or comprises SEQ ID NO: 11. HCDR3 is or comprises SEQ ID NO: 12, wherein Z is selected from Q and E. LCDR1 is or comprises SEQ ID NO: 5, wherein X is selected from S and D. LCDR2 is or comprises SEQ ID NO: 8. LCDR3 is or comprises SEQ ID NO: 9.
[0010] In one embodiment, Z is E. In another embodiment, Z is Q.
[0011] In one embodiment, X is D. In another embodiment, X is S.
[0012] In one embodiment, HCDR1 is or comprises SEQ ID NO: 10, HCDR2 is or comprises SEQ ID NO: 11, HCDR3 is or comprises SEQ ID NO: 13, LCDR1 is or comprises SEQ ID NO: 6, LCDR2 is or comprises SEQ ID NO: 8 and LCDR3 is or comprises SEQ ID NO: 9.
[0013] In one embodiment, the LCVR is or comprises SEQ ID NO: 17 and the HCVR is or comprises SEQ ID NO: 15, wherein a is selected from Q and pyroglutamic acid. a is Q.
[0014] In one embodiment, the antibody has a heavy chain (HC) and a light chain (LC), wherein the amino acid sequence of the HC is or comprises SEQ ID NO: 19, where X1 is selected from Q and pyroglutamic acid, X2 is G or absent, and X3 is K or absent, and the amino acid sequence of the LC is or comprises SEQ ID NO: 21. In one embodiment, X1 is Q, X2 is G, and X3 is K.
[0015] In one embodiment, HCDR1 is or comprises SEQ ID NO: 10, HCDR2 is or comprises SEQ ID NO: 11, HCDR3 is or comprises SEQ ID NO: 14, LCDR1 is or comprises SEQ ID NO: 7, LCDR2 is or comprises SEQ ID NO: 8 and LCDR3 is or comprises SEQ ID NO: 9.
[0016] In one embodiment, the amino acid sequence of the LCVR is or comprises SEQ ID NO: 18 and the amino acid sequence of the HCVR is or comprises SEQ ID NO: 16, wherein a is selected from Q and pyroglutamic acid. a is Q.
[0017] In one embodiment, the antibody has a heavy chain (HC) and a light chain (LC), wherein HC is or comprises SEQ ID NO: 20, where X1 is selected from Q and pyroglutamic acid, X2 is G or absent, X3 is K or absent, and LC is or comprises SEQ ID NO: 22. In one embodiment, X1 is Q, X2 is G, and X3 is K.
[0018] In any of the above embodiments, the antibody may be an XCL1 antagonist.
[0019] In any of the above embodiments, the antibody may bind to human XCL2.
[0020] In any of the above embodiments, the antibody may be an XCL2 antagonist.
[0021] In any of the above embodiments, the antibody can bind to dimeric XCL1. The dimeric XCL1 can be homodimeric XCL1. The antibody can bind to XCL1 in a β-sheet configuration. The homodimeric XCL1 can bind to glycosaminoglycans on the surface of a cell.
[0022] In any of the above embodiments, the antibody can bind to dimeric XCL2. The dimeric XCL2 can be homodimeric XCL2. The antibody can bind to XCL2 in a β-sheet configuration. The homodimeric XCL2 can bind to glycosaminoglycans on the surface of a cell.
[0023] In any of the above embodiments, the antibody may bind to a heterodimeric complex comprising one monomer of XCL1 and one monomer of XCL2. In such embodiments, the antibody binds to at least one amino acid of the XCL1 monomer or at least one amino acid of the XCL2 monomer of the heterodimeric complex. The heterodimeric complex may bind to glycosaminoglycans on the surface of a cell.
[0024] In any of the above embodiments, the antibody does not bind to chemokines other than XCL1 and XCL2.
[0025] In one embodiment, the antibody comprises a heavy chain variable region (HCVR) having at least 95% sequence identity to SEQ ID NO:15 and a light chain variable region (LCVR) having at least 95% sequence identity to SEQ ID NO:17.
[0026] In one embodiment, the antibody comprises a heavy chain (HC) having at least 95% sequence identity to SEQ ID NO:19 and a light chain (LC) having at least 95% sequence identity to SEQ ID NO:21.
[0027] In one embodiment, the antibody comprises a heavy chain variable region (HCVR) having at least 95% sequence identity to SEQ ID NO:16 and a light chain variable region (LCVR) having at least 95% sequence identity to SEQ ID NO:18.
[0028] In one embodiment, the antibody comprises a heavy chain (HC) having at least 95% sequence identity to SEQ ID NO:20 and a light chain (LC) having at least 95% sequence identity to SEQ ID NO:22.
[0029] In one embodiment, the antibody binds to an epitope of XCL1 that includes one or more amino acids of SEQ ID NO: 27. In one embodiment, the antibody binds to two or more amino acids of SEQ ID NO: 27. In an embodiment, the antibody binds to three or more amino acids of SEQ ID NO: 27.
[0030] In one embodiment, the antibody binds to one or more amino acids of SEQ ID NO:29.
[0031] In one embodiment, the antibody binds to an epitope of XCL1 that comprises one or more amino acids of SEQ ID NO: 28. In one embodiment, the antibody binds to two or more amino acids of SEQ ID NO:28.
[0032] In embodiments, the antibody binds to an epitope of XCL1 comprising one or more amino acids of SEQ ID NO: 27 and one or more amino acids of SEQ ID NO: 28. In one embodiment, the antibody binds to two or more amino acids of SEQ ID NO: 27 and two or more amino acids of SEQ ID NO: 28. In one embodiment, the antibody binds to one or more amino acids of SEQ ID NO: 29.
[0033] In one embodiment, the antibody has a human IgG1 isotype.
[0034] The present disclosure also provides pharmaceutical compositions comprising an antibody as described in some of the above embodiments and one or more pharma- ceutically acceptable carriers, diluents, or excipients.
[0035] The disclosure provides a method of treating alopecia areata, vitiligo, asthma, psoriasis, multiple sclerosis, psoriasis, rheumatoid arthritis, or ulcerative colitis in a subject in need thereof, comprising administering to the subject an effective amount of an antibody or pharmaceutical composition described herein.
[0036] The disclosure provides antibodies or pharmaceutical compositions for use in therapy, for example, for use in treating alopecia areata, vitiligo, asthma, psoriasis, multiple sclerosis, rheumatoid arthritis, or ulcerative colitis.
[0037] The disclosure provides use of an antibody or pharmaceutical composition in the manufacture of a medicament for the treatment of alopecia areata, vitiligo, asthma, psoriasis, multiple sclerosis, rheumatoid arthritis, or ulcerative colitis.
[0038] In one aspect, a nucleic acid is provided that comprises a sequence encoding SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, or SEQ ID NO:26. In one aspect, a vector is described that comprises a first nucleic acid sequence encoding SEQ ID NO:23 or SEQ ID NO:25 and a second nucleic acid sequence encoding SEQ ID NO:24 or SEQ ID NO:26, as well as a cell comprising such a vector. In one embodiment, a method of producing an antibody is disclosed that comprises culturing the cell under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium. In one embodiment, an antibody produced by culturing the cell under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium is disclosed.
[0039] In one embodiment, a protein complex is provided, comprising a dimeric XCL1 and an antibody bound to the dimeric XCL1. The dimeric XCL1 can be a homodimeric XCL1. The antibody can bind to at least one amino acid residue on each monomer unit of the dimeric XCL1.
[0040] In one embodiment, a protein complex is provided, comprising a dimeric XCL2 and an antibody bound to the dimeric XCL2. The dimeric XCL2 can be a homodimeric XCL2. The antibody can bind to at least one amino acid residue on each monomer unit of the dimeric XCL2.
[0041] In one aspect, a protein complex is provided comprising a heterodimer composed of a monomeric unit of XCL1 and a monomeric unit of XCL2 and an antibody bound to the heterodimer, in which the antibody may bind to at least one amino acid residue of XCL1, or at least one amino acid residue of XCL2, or at least one residue of XCL1 and at least one residue of XCL2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0042] As used herein, the term "antibody" refers to an immunoglobulin molecule that binds to an antigen. Antibody embodiments include monoclonal antibodies, polyclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, bispecific or multispecific antibodies, or conjugated antibodies. The antibody may be of any class (e.g., IgG, IgE, IgM, IgD, IgA) and any subclass (e.g., IgG1, IgG2, IgG3, IgG4).
[0043] An exemplary antibody of the present disclosure is an immunoglobulin G (IgG) type antibody composed of four polypeptide chains: two heavy chains (HC) and two light chains (LC) cross-linked via interchain disulfide bonds. The amino terminal portion of each of the four polypeptide chains contains a variable region of about 100-125 or more amino acids that is primarily responsible for antigen recognition. The carboxy terminal portion of each of the four polypeptide chains contains a constant region that is primarily responsible for effector function. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region. Each light chain is composed of a light chain variable region (VL) and a light chain constant region. The IgG isotype can be further divided into subclasses (e.g., IgG1, IgG2, IgG3, and IgG4).
[0044] The VH and VL regions can be further subdivided into hypervariable regions, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). The CDRs are exposed on the surface of the protein and are the regions of the antibody that are important for antigen-binding specificity. Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Herein, the three CDRs of the heavy chain are referred to as "HCDR1, HCDR2, and HCDR3" and the three CDRs of the light chain are referred to as "LCDR1, LCDR2, and LCDR3". The CDRs contain most of the residues that form specific interactions with the antigen.The assignment of amino acid residues to CDRs can be done using the standard methods published by Kabat (Kabat et al., "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991)), Chothia (Chothia et al., "Canonical structures for the hypervariable regions of immunoglobulins," Journal of Molecular Biology, 196, 901-917 (1987); Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins," Journal of Molecular Biology, 273, 927-948 (1997)), North (North et al., "A New Clustering of Antibody CDR Loop Conformations," Journal of Molecular Biology, 406, 228-256 (2011)), or IMGT (the international standard available at www.imgt.org). This can be done according to well-known schemes, including those described in the ImMunoGeneTics database; see Lefranc et al., Nucleic Acids Res. 1999;27:209-212).
[0045] Embodiments of the present disclosure also include antibody fragments or antigen-binding fragments that include at least a portion of an antibody that retains the ability to specifically interact with an antigen or an epitope of an antigen, such as Fab, Fab', F(ab')2, Fv fragments, scFv antibody fragments, scFab, disulfide-linked Fv (sdFv), Fd fragments, as used herein.
[0046] The antibody of the present invention is a monoclonal antibody. A monoclonal antibody is an antibody that is derived from a single copy or clone, including, for example, any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Monoclonal antibodies can be produced, for example, by hybridoma technology, recombinant technology, phage display technology, synthetic technology, such as CDR grafting, or a combination of such technologies or other technologies known in the art.
[0047] Methods for producing and purifying antibodies are well known in the art and can be found, for example, in Harlow and Lane (1988), Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring harbor, NY, chapters 5-8 and 15, ISBN 0-87969-314-2. For example, mice or rabbits, including transgenic mice or rabbits known in the art, may be immunized with human XCL1 or a portion thereof, and the resulting antibodies can be collected, screened, purified, and the amino acid sequence determined using conventional methods well known in the art.
[0048] In certain embodiments of the invention, the antibody, or nucleic acid encoding the antibody, is provided in isolated form. As used herein, the term "isolated" refers to a protein, polypeptide, or nucleic acid that is free or substantially free from other macromolecular species that are found within a cellular environment.
[0049] The antibodies of the present invention can be prepared and purified using known methods. For example, cDNA sequences encoding HC (e.g., the amino acid sequence shown by SEQ ID NO: 19 or SEQ ID NO: 20) and LC (e.g., the amino acid sequence shown by SEQ ID NO: 21 or SEQ ID NO: 22) can be cloned and engineered into a GS (glutamine synthetase) expression vector. In one example, the antibody has a heavy chain having the amino acid sequence shown by SEQ ID NO: 19 and a light chain having the amino acid sequence shown by SEQ ID NO: 21, and in such an example, the cDNA sequences that can be used to express the chains are provided by SEQ ID NO: 23 and SEQ ID NO: 24, respectively. In another example, the antibody has a heavy chain having the amino acid sequence shown by SEQ ID NO: 20 and a light chain having the amino acid sequence shown by SEQ ID NO: 22, and in this example, the cDNA sequences that can be used to express the chains are provided by SEQ ID NO: 25 and SEQ ID NO: 26, respectively.
[0050] The engineered immunoglobulin expression vector can then be stably transfected into CHO cells. As those skilled in the art will appreciate, mammalian expression of antibodies will typically result in glycosylation at the highly conserved N-glycosylation site in the Fc region. Stable clones can be verified for expression of antibodies that specifically bind to human XCL1 (e.g., represented by a recombinantly produced peptide comprising SEQ ID NO:1). Positive clones can be expanded in serum-free culture medium for antibody production in bioreactors. The medium into which the antibody is secreted can be purified by conventional techniques. For example, the medium can be conveniently applied to a Protein A or G Sepharose FF column equilibrated with a compatible buffer, such as phosphate-buffered saline. The column is washed to remove non-specifically bound components. Bound antibodies can be eluted, for example, by a pH gradient, and antibody fractions can be detected, for example, by SDS-PAGE, and then pooled. The antibodies can be concentrated and / or sterile filtered using common techniques. Soluble aggregates and multimers can be effectively removed by common techniques including size exclusion, hydrophobic interaction, ion exchange, or hydroxyapatite chromatography. The product can be immediately frozen, for example at -70°C, or lyophilized.
[0051] The antibody of the present invention can be used for the treatment of patients. More specifically, the antibody of the present invention is expected to be useful for the treatment of immune-mediated diseases or disorders, including alopecia areata, vitiligo, asthma, RA, MS, UC, psoriasis, and type 1 diabetes. As used interchangeably herein, "treatment" and / or "treating" and / or "treating" are intended to refer to any process that may slow, hinder, inhibit, control, stop, or reverse the progression of the disorders described herein, but do not necessarily indicate the complete elimination of all symptoms of the disorders. Treatment includes the administration of the antibody of the present invention, or a pharmaceutical composition thereof, for the treatment of a disease or condition in a human that would benefit from the reduction of XCL1 and / or XCL2 activity, and includes (a) inhibiting further progression of the disease, i.e., arresting its onset, or (b) relieving the disease, i.e., causing regression of the disease or disorder, or relieving its symptoms or complications.
[0052] As used interchangeably herein, the terms "patient," "subject," and "individual" refer to a human. In certain embodiments, the patient is further characterized by a disease, disorder, or condition (e.g., an immune-mediated disease) that would benefit from reduced XCL1 and / or XCL2 activity. In other embodiments, the patient is further characterized by being at risk for developing an immune-mediated disease, disorder, or condition that would benefit from reduced XCL1 and / or XCL2 activity.
[0053] As referred to herein, the term "epitope" refers to the amino acid residues of an antigen that are bound by an antibody. An epitope can be a linear epitope, a conformational epitope, or a hybrid epitope.
[0054] The term "epitope" may be used in reference to a structural epitope, which may, according to some embodiments, be used to describe the area of an antigen that is covered by an antibody (e.g., the footprint of the antibody when bound to the antigen). In some embodiments, a structural epitope may describe amino acid residues of an antigen that are within a particular proximity (e.g., within a particular number of angstroms) of amino acid residues of an antibody.
[0055] The term "epitope" may also be used in reference to a functional epitope, which, according to some embodiments, may be used to describe amino acid residues of an antigen that interact with amino acid residues of an antibody in a manner that contributes to the binding energy between the antigen and the antibody.
[0056] Epitopes can be determined according to different experimental techniques, also called "epitope mapping techniques". It is understood that epitope determination may vary based on the different epitope mapping techniques used, and may also vary with different experimental conditions used, for example, due to conformational changes or cleavage of the antigen induced by the specific experimental conditions. Epitope mapping techniques are known in the art, including, but not limited to, X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, site-directed mutagenesis, species swap mutagenesis, alanine scanning mutagenesis, hydrogen-deuterium exchange (HDX), and cross-blocking assays (see, for example, Rockberg and Nilvebrant, Epitope Mapping Protocols: Methods in Molecular Biology, Humana Press, 30th Annual Meeting of the American Academy of Sciences, 2011, pp. 1171-1175, 2011). rd ed.2018).
[0057] As used herein, the terms "bind", "binds", and "binding", unless otherwise indicated, refer to the ability of a protein or molecule to form a chemical bond or attractive interaction with another protein or molecule, resulting in close proximity of the two proteins or molecules as determined by common methods known in the art. With particular reference to the binding of an antibody to an antigen, the terms "bind", "binds", and "binding" refer to the interaction of one or more of the CDRs of the hypervariable region of the antibody with the antigen, i.e., specific binding may be conferred to the antibody by one or more of the CDRs.
[0058] As used herein, the terms "specifically bind" and "specific binding" refer to a situation in which one member of a specific binding pair does not significantly bind to molecules other than its specific binding partner. For example, a particular antibody can be said to specifically bind to XCL1 and XCL2, but not to other similar proteins (e.g., chemokines, etc.). Antibodies can be assayed using techniques available in the art, such as competitive ELISA or K-ELISA using BIACORE or KINEXA assays. D An antigen can be said to specifically bind if it binds at least about 50% greater, or 2-fold greater, or 20-fold greater, or 50-fold greater, or 100-fold greater than it binds to a different antigen or non-antigen target, as measured by measurement.
[0059] The antibodies of the invention can be prepared by methods well known in the art and can be incorporated into pharmaceutical compositions comprising an antibody of the invention and one or more pharma- ceutically acceptable carriers and / or diluents (see, for example, Remington, The Science and Practice of Pharmacy, 22(1), which generally provides an overview of formulation techniques known to the practitioner). ndEdition, Loyd V., Ed., Pharmaceutical Press, 2012). Carriers suitable for pharmaceutical compositions include any material which, when combined with the antibody of the invention, retains the activity of the molecule and is non-reactive with the patient's immune system.
[0060] A pharmaceutical composition comprising an antibody of the invention may be administered by parenteral routes (e.g., subcutaneous, intravenous, intraperitoneal, intramuscular, or transdermal) to a patient at risk for or exhibiting a disease or disorder described herein. The pharmaceutical composition of the invention contains an "effective" amount or a "therapeutically effective" amount (used interchangeably herein) of an antibody of the invention. An effective amount refers to the amount (at the dosage and duration and means of administration) necessary to achieve the desired therapeutic result. The effective amount of an antibody may vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody to elicit a desired response in the individual. An effective amount is also one in which any toxic or detrimental effects of the antibody of the invention are outweighed by the therapeutically beneficial effects.
[0061] As used in this disclosure in relation to two or more amino acid sequences, percent homology refers to two or more sequences that have a specified percentage of the same amino acid residues when compared and aligned for maximum correspondence, as determined using a sequence comparison algorithm (e.g., BLASTP and BLASTN, or other algorithms available to those skilled in the art) or by visual inspection. Depending on the application, the percent homology can be over a region of the sequences being compared, e.g., over a functional domain, or over the entire length of the two sequences being compared. As an example, the percent homology of a sequence can be compared to a reference sequence. For example, when using a sequence comparison algorithm, a test sequence and a reference sequence can be input into a computer (and subsequence coordinates can be further specified, if necessary, along with sequence algorithm program parameters). The sequence comparison algorithm then calculates the percent sequence identity or homology of the test sequence relative to the reference sequence based on the specified program parameters. Exemplary sequence alignment and / or homology algorithms are available through Smith & Waterman, Adv. Appl. Math. 2:482 (1981), Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), GAP, BESTFIT, FASTA, and TFASTA (the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally, Ausubel et al., infra). One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990).Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov / ).
[0062] It is known that in some cases, recombinant production of antibodies can result in antibody modification. Examples of such modifications include the loss of lysine or glycine at the C-terminus of HC, conversion of glutamine or glutamic acid to pyroglutamic acid at the N-terminus of heavy chain, or conversion of glutamine or glutamic acid to pyroglutamic acid at the N-terminus of lambda light chain. This can result in the production of a heterogeneous mixture of antibodies, including those with no modification, a single modification, or multiple modifications. The antibodies of the present disclosure may undergo such modifications and are encompassed by the claims derived therefrom.
[0063] In one embodiment, an antibody of the invention binds to and neutralizes XCL1, hi one embodiment, an antibody of the invention binds to and neutralizes XCL2.
[0064] In one embodiment, the antibodies of the invention impede or prevent the migration of cells expressing XCR1. In a specific embodiment, the antibodies of the invention neutralize dendritic cell migration. In one embodiment, the dendritic cell is a cDC1.
[0065] In one embodiment, the antibody of the invention is -11 K for XCL1 below M D In one embodiment, the antibody of the invention has a -11 K for XCL2 below M D has.
[0066] In one embodiment, the antibodies of the invention bind to XCL1 in a β-sheet monomeric conformation.In one embodiment, the antibodies of the invention bind to XCL1 in a dimeric conformation.
[0067] In one embodiment, the antibodies of the invention bind to XCL2 in a β-sheet monomeric conformation.In one embodiment, the antibodies of the invention bind to XCL2 in a dimeric conformation.
[0068] In one embodiment, the antibody disclosed herein binds to homodimeric XCL1. In an embodiment, the antibody disclosed herein binds to homodimeric XCL2. In one embodiment, the antibody disclosed herein binds to a heterodimeric complex comprising one monomer of XCL1 and one monomer of XCL2. In one embodiment, the antibody disclosed herein binds to free monomeric XCL1 and / or XCL2, and / or free homodimeric XCL1, and / or free homodimeric XCL2, and / or free heterodimers of XCL1 and XCL2. In one embodiment, the antibody disclosed herein binds to homodimeric XCL1 bound to GAG, and / or homodimeric XCL2 bound to GAG, and / or heterodimers of XCL1 and XCL2 bound to GAG.
[0069] In one embodiment, the antibody binds to the sequence set forth by SEQ ID NO:29 (i.e., threonine 16, glutamine 17, arginine 18, leucine 19, and proline 20). In an embodiment, the antibody binds to the sequence set forth by SEQ ID NO:29 along with lysine 42 and arginine 43. In one embodiment, the antibody of the invention binds to one or more amino acids of SEQ ID NO:27, or to two or more amino acids of SEQ ID NO:27, or to three or more amino acids of SEQ ID NO:27. In one embodiment, the antibody of the invention binds to one or more amino acids of SEQ ID NO:28, or to two or more amino acids of SEQ ID NO:28. In an embodiment, the antibody of the invention binds to one or more amino acids of SEQ ID NO:29. In one embodiment, the antibody of the invention binds to one or more amino acids of SEQ ID NO:27 and one or more amino acids of SEQ ID NO:28, or to two or more amino acids of SEQ ID NO:27 and two or more amino acids of SEQ ID NO:28.
[0070] In one embodiment, the antibodies of the invention have anti-inflammatory activity and can be used as therapeutic agents.
[0071] In one aspect, an antibody of the invention binds to XCL1 and / or XCL2 but does not specifically bind to another chemokine. EXAMPLES
[0072] Example 1: Expression of recombinant XCL1 and its mutants, and XCL2 Each protein (human XCL1, SEQ ID NO:1; human XCL2, SEQ ID NO:2; CC3, SEQ ID NO:3; and CC5, SEQ ID NO:4) was expressed as a fusion protein consisting of an 8xHis tag at the N-terminus, a known BRIL fusion protein, an enterokinase (EK) cleavage site, and then the specific protein (such as XCL1) at the C-terminus. Stable CHO-K1 cell lines were generated for each protein using fusion protein expression plasmids by methods known in the art. The fusion proteins were expressed and secreted in chemically defined medium. The medium was collected and the fusion proteins were captured on a Ni-IMAC column (e.g., available from Pierce) and eluted with 375 mM imidazole at pH 7.5. The Ni-IMAC pool was dialyzed into EK digestion buffer (20 mM Tris, 100 mM NaCl, 5 mM CaCl2, pH 8) and the fusion proteins were incubated with EK overnight. The released proteins were captured with Capto-S resin (Cytiva Cat. No. 17544101) and then polished by size exclusion chromatography (Superdex 75 - Cytiva Cat. No. 28989333). Protein identity was confirmed by mass spectrometry.
[0073] Example 2: Expression of anti-XCL1 antibodies Exemplary anti-XCL1 antibodies of the present invention are presented in Table 1 below. Antibodies were produced in a stable CHO-K1 cell line in chemically defined medium. They were captured on PRISMA resin (Cytiva-cat. no. 1754981) and eluted with pH 3 buffer. The PRISMA pool was brought to pH 5 to precipitate host cell proteins (HCPs). Proteins were polished by anion exchange chromatography (AEX) using a POROS 50HS (Thermo Fisher cat. no. 1335906) and then dialyzed into 10 mM histidine, 275 mM sucrose, pH 6. Material was analyzed by analytical size exclusion chromatography (SEC) and confirmed using mass spectrometry.
[0074] [Table 1]
[0075] A control antibody that specifically binds to monomeric XCL1 (i.e., binds to CC3 with high affinity and does not bind to CC5; see Examples below) having an HC amino acid sequence shown by SEQ ID NO: 27 and an LC amino acid sequence shown by SEQ ID NO: 28. cDNA sequences that can be used to express the HC and LC are shown by SEQ ID NO: 29 and SEQ ID NO: 30, respectively. This antibody is referred to herein as the monomer-binding control (MBC).
[0076] The relationship of the various regions of the exemplified anti-XCL1 antibodies is as follows (the amino acid numbering applies a linear numbering scheme and the assignment of amino acids to the variable domains is based on the International Immunogenetics Information System® available at www.imgt.org): The assignment of amino acids to the CDR domains of each exemplified antibody is based on the well-known North numbering scheme, except for HCDR2, whose C-terminus is based on the well-known Kabat numbering scheme.
[0077] The exemplified antibodies of the present disclosure are identified as possessing high binding affinity and being chemically and physically stable, including aggregation and solubility, consistent with therapeutic parental administration. The exemplified antibodies of the present disclosure are also identified as possessing low immunogenicity (including low non-specific binding and / or serum binding) and possessing pharmacokinetic properties consistent with therapeutic parental administration for the treatment of immune-mediated diseases. In one aspect, the antibodies disclosed herein are human antibodies of IgG1 isotype. The antibodies disclosed herein are monoclonal antibodies. Antibodies of other isotypes (e.g., IgG4, etc.) are also contemplated by the present disclosure.
[0078] Example 3: Characterization of XCL1 mutants CC3 and CC5 XCL1 is a denatured protein that readily undergoes major conformational rearrangements depending on salt and temperature conditions: high salt and low temperature (10°C) favor an active monomeric conformation with an α-helical motif typical of the canonical chemokine fold that can signal through its cognate receptor, XCR1, whereas low salt and higher temperature (40°C) favor an inactive β-sheet conformation that can dimerize and bind to endogenous glycosaminoglycans (GAGs).
[0079] To study the properties of each conformation separately, engineered mutant proteins were expressed and purified. CC3 (SEQ ID NO: 3) is an engineered mutant of XCL1 stabilized in an active α-helix-containing monomeric conformation through the creation of a disulfide bond when residues 21 and 59 are mutated to cysteines (V21C / V59C). Similarly, mutations at residues 36 and 49 to cysteines (A36C / A49C) create an alternative disulfide structure that stabilizes an inactive β-sheet conformation that tends toward a dimeric state, called CC5 (SEQ ID NO: 4). These mutants are known in the art and were prepared as specified in the literature (see Biopolymers 2021 Oct, 112(10):e23402 doi:10.1002 / bip.23402. Epub 2020 Sep 28).
[0080] XCR1 is expressed on several types of dendritic cells (DCs), primarily type 1 conventional dendritic cells (cDC1s). cDC1s are antigen presenting cells (APCs) suitable for antigen presentation to CD8+ T cells in the context of major histocompatibility complex I. As CD8+ T cells secrete XCL1, a chemoergic gradient is generated that attracts XCR1-bearing cells to the site of CD8+ T cells (e.g., within tumor or autoimmune sites) to enhance the immune response. See Dorner et al., Immunity 31 (2009) 823-833; Audsley et al. Cells 9 (2020) 565 1-22.
[0081] Recombinant human XCL1, CC3, and CC5 were prepared and evaluated in a migration assay utilizing the murine Ba / F3 cell line, which stably overexpresses human XCR1. The cell line migrates towards an XCL1 chemokine gradient in vitro in a 5 μM Boyden chamber assay plate. Various concentrations of XCL1 are added to the lower chamber and the assay is set up with 150,000 cells / well in the upper chamber. Cells are allowed to migrate for approximately 4 hours at 37° C. and transferred cells are quantified using a luminescent cell viability readout. The results are shown in Table 2 below.
[0082] [Table 2]
[0083] For CC3, the EC of approximately 114.7 nM compared to wild-type XCL1 (858.4 nM) 50 A strong migration occurs at CC3. No migration was observed for CC5. These data confirm observations in the literature showing that recombinant CC3 and CC5 represent two distinct conformations of XCL1.
[0084] Example 4: Binding kinetics and affinity The affinity and binding kinetics of the antibodies and MBC of the present invention to human XCL1, human XCL2, mouse XCL1, cynomolgus (cyno) XCL1, and rat XCL1 were determined by surface plasmon resonance using Biacore 8K (GE Healthcare). The procedure generally follows the "Instrument Handbook". The antibodies were first captured on a Biacore Protein A chip, followed by running serial concentrations of antigen from 400 nM to 0.039 nM in two-fold serial dilutions in PBS-P20-BSA (0.1% surfactant P20, 0.1 mg / mL BSA). All measurements are performed at 25°C.
[0085] A multi-cycle kinetic setup is used, running each analyte concentration in a separate cycle with the surface regenerated after each sample injection. The regeneration is optimized to maintain consistent surface properties from cycle to cycle. Each cycle begins with a 3 min injection of antibody (approximately 150 response unit (RU) capture level) at a flow rate of 10 μl / min, followed by a 3 min injection of antigen at a flow rate of 50 μl / min and a 15 min dissociation phase in PBS-P20-BSA. The chip surface was then regenerated by three 30 s injections of pH 1.5, 10 mM glycine buffer at a flow rate of 50 μl / min. The data were fitted to a 1:1 binding model to determine the k a and k d Derive K dwas calculated.
[0086] Essentially following the above procedure, the following parameters are obtained for the antibodies in the present invention:
[0087] [Table 3]
[0088] Notably, antibodies 1 and 2 bind with good affinity to CC5 but not to CC3, whereas the reverse is observed for monomer-specific binding of MBC. This may be because the introduction of a cysteine in CC3 may interfere with the epitope to which antibodies 1 and 2 bind. Crystallography experiments support that antibodies 1 and 2 bind to the β-sheet monomeric form of XCL1. In one aspect, antibodies 1 and 2 may be said to bind primarily and preferentially to the dimeric form, and these results demonstrate that antibodies 1 and 2 can bind to homodimeric XCL1.
[0089] Example 5: Neutralization of XCL1 and XCL2: Human XCR1 translocation assay XCL1 and XCL2 are highly conserved chemokines with chemoactive activity mediated through the XCR1 receptor. The mouse cell line Ba / F3 was stably transfected with the human XCR1 receptor to assess the ability of XCL1 / 2 to induce migration in vitro.
[0090] For this assay, 150,000 recombinant hXCR1 / Ba / F3 cells were seeded into the top chamber of a Boyden chamber assay plate at 5 μM, and XCL1 concentrations were empirically determined for each species added to the bottom chamber. Cells were allowed to migrate towards an XCL1 / 2 gradient for approximately 4 hours, and cells in the bottom chamber were assayed by a luminescent cell viability readout. In this assay, human XCL1, human XCL2, mouse, rat, and cynomolgus XCL1 all induce migration. After performing a ligand dose response, a single concentration of XCL1 / 2 was selected and used in the bottom chamber of the Boyden chamber plate along with a dose response for each mAB tested. Neutralizing IC of each antibody was determined.50 As can be seen in Table 4 below, all antibodies were able to neutralize human XCL1 and XCL2, as well as rat, mouse, and cynomolgus XCL1.
[0091] [Table 4]
[0092] The results provided in Tables 3 and 4 demonstrate that both exemplified antibodies bind to both XCL1 and XCL2 with high affinity and neutralize both chemokines in in vitro assays. It will therefore be appreciated that the antibodies of the present disclosure are therapeutically useful for binding and neutralizing XCL1, XCL2, or both. It will be appreciated that the antibodies disclosed herein bind to homodimeric XCL1, and due to the sequence similarity between XCL1 and XCL2, the antibodies bind to homodimeric XCL2. The antibodies also bind to heterodimeric complexes that may form and include one monomer of XCL1 and XCL2. The antibodies of the present disclosure may bind to free monomeric XCL1 or XCL2, or free homodimeric XCL1, or free homodimeric XCL2, or free heterodimers of XCL1 and XCL2. The antibodies of the disclosure may also bind to homodimeric XCL1 bound to GAG, or homodimeric XCL2 bound to GAG, or a heterodimer of XCL1 and XCL2 bound to GAG.
[0093] Example 6: Neutralization of XCL1 activity by antibodies: dendritic cell migration XCL1 and XCL2 stimulate the migration of XCR1 expressing conventional type 1 dendritic cells (cDC1). To demonstrate XCL1 / 2 antibody neutralizing activity, human cDC1 cells were differentiated from CD34+ stem cells and their migration through Boyden chambers towards XCL1 was measured by flow cytometry. Briefly, human umbilical cord blood derived CD34+ cells were differentiated for 3 weeks in a cytokine cocktail on a feeder layer expressing DLL1 (adapted from Balan et al. doi:10.1016 / j.celrep.2018.07.033). Cells were enriched using a myeloid dendritic cell kit (StemCell; lineage negative, HLA-DR + , CD11c + ). 10 ng / mL of XCL1 + antibody dose titrations were pre-incubated in triplicate for 1 hour and added to the lower chamber of the Boyden chamber. Antibodies used were Antibody 1, Antibody 2, and hIgG1-AAS isotype control antibody. 150,000 enriched differentiated cells were added to the upper chamber of the Boyden chamber and incubated for 2 hours. Migrated human cDC1 cells in the lower chamber were stained (live / dead, CLEC9A + , XCR1 + ) and counted. The XCL1 / 2 antibody of the present invention completely inhibited cDC1 migration toward XCL1 over three repeated experiments, and IC 50 The geometric means of the values (nM) and associated errors (delta method) are shown in Table 5.
[0094] [Table 5]
[0095] Example 7: Anti-inflammatory effects of antibodies in mice The immunosuppressive activity of antibodies 1 and 2 was evaluated in a mouse model of oxazolone-induced delayed type hypersensitivity on mouse ears and compared to an anti-CD8 depleting antibody (Bio X-cells #BE0117). Mice were treated with anti-XCL1 / 2 antibodies on day 0 and approximately 1 hour later sensitized on the shaved ventral surface with 3% oxazolone in acetone. On day 6, mice were challenged with 2% oxazolone on the ears and changes in ear swelling were measured on day 7. Results are shown in Table 6 as delta ear thickness with anti-XCL1 / 2 antibodies compared to the corresponding isotypes.
[0096] [Table 6]
[0097] Example 8: Epitope Mapping and Determination The binding sites for the exemplified antibodies on the surface of XCL1 were determined by HDX and X-ray crystallography, techniques well known in the art. By HDX, antibodies 1 and 2 were found to bind to a non-linear epitope formed by residues within residues 12-20 (SEQ ID NO:27) and residues 35-46, SEQ ID NO:28. The X-ray crystal structure (to a resolution of 2.77 angstroms) of the fragment antigen-binding region (Fab) complexed with human XCL1 further suggests that the specific residues involved in binding are those whose sequence is depicted by SEQ ID NO:29 (i.e., threonine 16, glutamine 17, arginine 18, leucine 19, and proline 20), as well as lysine 42 and arginine 43. Thus, the antibodies of the invention may bind to one or more amino acids of SEQ ID NO:27, or to two or more amino acids of SEQ ID NO:27, or to three or more amino acids of SEQ ID NO:27. The antibodies of the invention may bind to one or more amino acids of SEQ ID NO:28, or to two or more amino acids of SEQ ID NO:28. Antibodies of the invention may bind to one or more amino acids of SEQ ID NO: 29. Antibodies of the invention may bind to one or more amino acids of SEQ ID NO: 27 and one or more amino acids of SEQ ID NO: 28, or to two or more amino acids of SEQ ID NO: 27 and two or more amino acids of SEQ ID NO: 28.
[0098] The antibodies exemplified herein bind to a non-linear epitope of XCL1 / XCL2. In one example, the antibody binds to a monomeric β-sheet conformation of XCL1 or XCL2. In another example, the antibody binds to a dimeric form of XCL1 or XCL2. In such a case, the antibody may bind to a single one of the two monomeric subunits of the chemokine that together define a dimer. For example, the antibody may bind to the amino acid residues defined by SEQ ID NO:29, as well as lysine 42 and / or arginine 43 of the first monomeric unit of XCL1. The present disclosure also contemplates antibodies that bind to dimeric XCL1 or XCL2 by binding to a non-linear epitope that includes residues of both monomers of the dimer. Another binding mode contemplated herein is a mode that binds to monomeric β-sheet XCL1 or XCL2 in such a way that dimerization is prevented.
[0099] Example 9: GAG-binding assay As mentioned, the β-sheet conformation of XCL1 / 2 allows it to dimerize and is unable to bind to the XCR1 receptor. Instead, in this form, XCL1 / 2 binds to cell surface GAGs, which are thought to help establish a chemoattractant gradient. Antibodies 1 and 2 bind preferentially to the dimeric form in the β-sheet conformation, and their ability to bind to XCL1 / 2 dimers bound to cell surface GAGs was studied using flow cytometry.
[0100] 293T cells were incubated for 1 hour with various preparations of XCL1 or XCL2 at 1 μg / mL and either Antibody 1, Antibody 2, or hIgG1-AAS isotype control antibody ("Control") at 100 nM. This was followed by staining with anti-human-Fc / PE secondary antibody (Life Technologies 12-4998-82) to detect antibody-XCL1 / 2 complexes bound to cell surface GAGs. In another condition, binding of antibody-XCL1 / 2 complexes was performed in the presence of 100 ug / mL heparin to demonstrate the specificity of GAG binding. Mean fluorescence intensity (MFI) was measured by flow cytometry for each condition. Experiments were repeated three times and the mean MFI + / - standard deviation across experiments is shown in Table 7 below.
[0101] [Table 7]
[0102] The above results demonstrate that antibodies 1 and 2 bind to inactive or dimeric XCL1 on the cell surface, and together with the results of Example 6 demonstrate that antibodies 1 and 2 can bind to inactive XCL1 and sequester it so that it does not activate XCR1.
[0103] Example 10: XCL1 specificity of exemplified antibodies A human serum binding assay was used to identify the non-specific targets of antibodies 1 and 2, as well as MBC. Each antibody was coated onto microwells and subsequently treated with serum. After overnight incubation, unbound serum proteins were washed away before eluting the antibody-bound proteins. These samples were digested with trypsin and peptides were identified by mass spectrometry.
[0104] Antibodies 1 and 2 did not bind to other chemokines, but MBC was found to bind significant amounts of a second off-target chemokine. Subsequent experiments demonstrated that MBC lost biological activity in the presence of high concentrations of this chemokine (i.e., similar to those expected in a physiological situation), while the other antibodies 1 and 2 were unaffected.
[0105] Sequence Listing SEQ ID NO: 1 Human XCL1 VGSEVSDKRTCVSLTTQRLPVSRIKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVVRSMDRKSNTRNNMIQTKPTGTQQSTNTAVTLTG
[0106] SEQ ID NO:2 Human XCL2 VGSEVSHRRTCVSLTTQRLPVSRIKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVVRSMDRKSNTRNNMIQTKPTGTQQSTNTAVTLTG
[0107] SEQ ID NO:3 CC3 VGSEVSDKRTCVSLTTQRLPCSRIKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDCVRSMDRKSNTRNNMIQTKPTGTQQSTNTAVTLTG
[0108] SEQ ID NO:4 CC5 VGSEVSDKRTCVSLTTQRLPVSRIKTYTITEGSLRCVIFITKRGLKVCCDPQATWVRDVVRSMDRKSNTRNNMIQTKPTGTQQSTNTAVTLTG
[0109] SEQ ID NO: 5. General formula for LCDR1 of antibodies 1 and 2 QASQXISDYLN, where X is selected from S and D.
[0110] SEQ ID NO:6 Antibody 1 light chain CDR1 QASQDISDYLN
[0111] SEQ ID NO:7 Antibody 2 Light Chain CDR1 QASQSISDYLN
[0112] SEQ ID NO: 8 Light chain CDR2 of antibodies 1 and 2 YDASAKQT
[0113] SEQ ID NO: 9 Light chain CDR3 of antibodies 1 and 2 QHYDNLGYYT
[0114] SEQ ID NO: 10 Heavy chain CDR1 of antibody 1 and 2 KASGYTFTSYYMV
[0115] SEQ ID NO: 11 Heavy chain CDR2 of antibody 1 and 2 VIDPSKGSTNYAQKFQG
[0116] SEQ ID NO: 12 HCDR3 CDR2 of antibody 1 and 2 AREGLZLLAFDI, where Z is selected from Q and E.
[0117] SEQ ID NO: 13 Antibody 1 Heavy Chain CDR3 AREGLELLA FDI
[0118] SEQ ID NO:14 Antibody 2 Heavy Chain CDR3 AREGLQLLAFDI
[0119] SEQ ID NO:15 Antibody 1 HCVR X a VQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMVWVRQAPGQGLEWMGVIDPSKGSTNYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGLELLAFDIWGQGTMVTVSS (wherein X is Q or pyroglutamic acid)
[0120] SEQ ID NO: 16 Antibody 2 HCVR X aVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMVWVRQAPGQGLEWMGVIDPSKGSTNYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGLQLLAFDIWGQGTMVTVSS (wherein X is Q or pyroglutamic acid)
[0121] SEQ ID NO:17 Antibody 1 LCVR DIQMTQSPSSLSASVGDRVTITCQASQDISDYLNWYQQKPGKAPKLLIYDASAKQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQHYDNLGYYTFGQGTKLEIK
[0122] SEQ ID NO: 18 Antibody 2 LCVR DIQMTQSPSSLSASVGDRVTITCQASQSISDYLNWYQQKPGKAPKLLIYDASAKQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQHYDNLGYYTFGQGTKLEIK
[0123] SEQ ID NO: 19 Antibody 1 HC X1VQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMVWVRQAPGQGLEWMGVIDPSKGSTNYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGLELLAFDIWGQGTMVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTL MISRTPEVTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPX2X3 (wherein X1 is Q or pyroglutamic acid, X2 is G or absent, and X3 is K or absent)
[0124] SEQ ID NO:20 Antibody 2 HC X1VQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMVWVRQAPGQGLEWMGVIDPSKGSTNYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGLQLLAFDIWGQGTMVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTL MISRTPEVTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPX2X3 (wherein X1 is Q or pyroglutamic acid, X2 is G or absent, and X3 is K or absent)
[0125] SEQ ID NO:21 Antibody 1 LC DIQMTQSPSSLSASVGDRVTITCQASQDISDYLNWYQQKPGKAPKLLIYDASAKQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQHYDNLGYYTFGQGTKLEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
[0126] SEQ ID NO: 22 Antibody 2 LC DIQMTQSPSSLSASVGDRVTITCQASQSISDYLNWYQQKPGKAPKLLIYDASAKQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQHYDNLGYYTFGQGTKLEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
[0127] SEQ ID NO:23 Antibody 1 heavy chain DNA sequence
[0128] Array number 24, antibody 1 light chain DNA sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAGGACATAAGCGACTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTACGATGCTTCCGCTAAACAAACAGGGGTCCCATCAAGGTTCAGTGGAAGTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGATATTGCAACATATTACTGTCAACATTATGATAATCTCGGATACTACACTTTTGGCCAAGGGACCAAGCTGGAGATCAAAagaactgtggcggcgccatctgtcttcatcttcccgccatctgatgagcagttgaaatccggaactgcctctgttgtgtgcctgctgaataacttctatcccagagaggccaaagtacagtggaaggtggataacgccctccaatcgggtaactcccaggagagtgtcacagagcaggacagcaaggacagcacctacagcctcagcagcaccctgacgctgagcaaagcagactacgagaaacacaaagtctacgcctgcgaagtcacccatcagggcctgagctcgcccgtcacaaagagcttcaacaggggagagtgc
[0129] Array number 25, antibody 2 heavy chain DNA sequence
[0130] SEQ ID NO:26 Antibody 2 light chain DNA sequence GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCGAGTCAGAGCATAAGCGACTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTACGATGCTTCCGCTAA ACAAACAGGGGTCCCATCAAGGTTCAGTGGAAGTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGATATTGCAACATATTACTGTCAACATTATGATAATTCCGATACTACACTTTTGGCCAAGGGACCAAGCTGGAGATCA AAAGAACTGTGGCGGCGCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCCGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAG GAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGC
[0131] SEQ ID NO: 27 XCL1 epitope 1 (antibodies 1 and 2) VSLTTQRLP
[0132] SEQ ID NO: 28 XCL1 epitope 2 (antibodies 1 and 2) RAVIFITKRGLK
[0133] SEQ ID NO: 29 XCL1 epitope 1 subsequence (antibodies 1 and 2) TQRLP
[0134] SEQ ID NO: 30 Antibody 1 HCVR without variable number QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMVWVRQAPGQGLEWMGVIDPSKGSTNYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGLELLAFDIWGQGTMVTVSS
[0135] SEQ ID NO: 31 Antibody 2 HCVR without variable number QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMVWVRQAPGQGLEWMGVIDPSKGSTNYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGLQLLAFDIWGQGTMVTVSS
[0136] SEQ ID NO: 32 Antibody 1 HC without variable numbers QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMVWVRQAPGQGLEWMGVIDPSKGSTNYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGLELLAFDIWGQG TMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0137] SEQ ID NO: 33 Antibody 2 HC without variable numbers QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMVWVRQAPGQGLEWMGVIDPSKGSTNYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGLQLLAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPPAEAPEAGGPSVFLFPPPKPKDTLMISRTPEVTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Claims
1. An antibody that binds to human XCL1 comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), the HCVR comprising complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3, and the LCVR comprising CDRs LCDR1, LCDR2, and LCDR3; said HCDR1 comprising SEQ ID NO: 10; said HCDR2 comprising SEQ ID NO: 11; the HCDR3 comprises SEQ ID NO: 12, wherein Z is selected from Q and E; said LCDR1 comprises SEQ ID NO:5, wherein X is selected from S and D; the LCDR2 comprises SEQ ID NO:8; An antibody wherein the LCDR3 comprises SEQ ID NO:
9.
2. The antibody of claim 1, wherein Z is E.
3. 3. The antibody of claim 1 or 2, wherein X is D.
4. The antibody of claim 1, wherein Z is Q.
5. 5. The antibody of claim 1 or 4, wherein X is S.
6. The antibody of any one of claims 1 to 3, wherein HCDR1 comprises SEQ ID NO: 10, HCDR2 comprises SEQ ID NO: 11, HCDR3 comprises SEQ ID NO: 13, LCDR1 comprises SEQ ID NO: 6, LCDR2 comprises SEQ ID NO: 8, and LCDR3 comprises SEQ ID NO:
9.
7. The LCVR comprises SEQ ID NO: 17 and the HCVR comprises SEQ ID NO: 15, wherein a The antibody of any one of claims 1 to 3 or 6, wherein is selected from Q and pyroglutamic acid.
8. X a The antibody of claim 7, wherein is Q.
9. The antibody comprises a heavy chain (HC) and a light chain (LC), the HC comprising SEQ ID NO: 19, wherein X 1 is selected from Q and pyroglutamic acid; X 2 is G or absent, and X 3 The antibody of any one of claims 1 to 3, 6, or 7, wherein: is K or absent, and the LC comprises SEQ ID NO:
21.
10. X 1 is Q and X 2 is G and X 3 The antibody of claim 9, wherein is K.
11. The antibody of any one of claims 1, 4, and 5, wherein HCDR1 comprises SEQ ID NO: 10, HCDR2 comprises SEQ ID NO: 11, HCDR3 comprises SEQ ID NO: 14, LCDR1 comprises SEQ ID NO: 7, LCDR2 comprises SEQ ID NO: 8, and LCDR3 comprises SEQ ID NO:
9.
12. The LCVR comprises SEQ ID NO: 18 and the HCVR comprises SEQ ID NO: 16, wherein a The antibody of any one of claims 1, 4, 5, and 11, wherein is selected from Q and pyroglutamic acid.
13. X a The antibody of claim 12, wherein is Q.
14. The antibody comprises a heavy chain (HC) and a light chain (LC), the HC comprising SEQ ID NO: 20, wherein X 1 is selected from Q and pyroglutamic acid; X 2 is G or absent, and X 3 The antibody of any one of claims 1, 4, 5, 11, and 12, wherein LC is K or absent, and LC comprises SEQ ID NO:
22.
15. X 1 is Q and X 2 is G and X 3 The antibody of claim 14, wherein is K.
16. The antibody of any one of claims 1 to 15, which is an XCL1 antagonist.
17. The antibody of any one of claims 1 to 15, wherein the antibody binds to human XCL2.
18. 18. The antibody of claim 17 which is an XCL2 antagonist.
19. The antibody of any one of claims 1 to 18, which binds to dimeric XCL1.
20. The antibody of any one of claims 1 to 19, wherein the dimeric XCL1 is a homodimeric XCL1.
21. The antibody of any one of claims 1 to 20, wherein the antibody binds to XCL1 in a β-sheet configuration.
22. The antibody of any one of claims 1 to 21, wherein the homodimeric XCL1 is bound to a glycosaminoglycan on the surface of a cell.
23. The antibody of any one of claims 1 to 22, which binds to dimeric XCL2.
24. The antibody of any one of claims 1 to 23, wherein the dimeric XCL2 is a homodimeric XCL2.
25. The antibody of any one of claims 1 to 24, wherein the antibody binds to at least one amino acid residue on each monomer unit of dimeric XCL2.
26. The antibody of any one of claims 1 to 25, wherein the homodimeric XCL2 is bound to a glycosaminoglycan on the surface of a cell.
27. The antibody of any one of claims 1 to 26, which binds to a heterodimeric complex comprising one monomer of XCL1 and one monomer of XCL2.
28. The antibody of any one of claims 1 to 27, wherein the antibody binds to at least one amino acid of the XCL1 monomer or at least one amino acid of the XCL2 monomer of the heterodimeric complex.
29. The antibody of any one of claims 1 to 28, wherein the heterodimeric complex is bound to a glycosaminoglycan on the surface of a cell.
30. The antibody of any one of claims 1 to 29, which does not bind to chemokines other than XCL1 and XCL2.
31. An antibody that binds to human XCL1, comprising a heavy chain variable region (HCVR) having at least 95% sequence identity to SEQ ID NO:15 and a light chain variable region (LCVR) having at least 95% sequence identity to SEQ ID NO:
17.
32. The antibody of claim 31 , comprising a heavy chain (HC) having at least 95% sequence identity to SEQ ID NO: 19 and a light chain (LC) having at least 95% sequence identity to SEQ ID NO:
21.
33. An antibody that binds to human XCL1, comprising a heavy chain variable region (HCVR) having at least 95% sequence identity to SEQ ID NO:16 and a light chain variable region (LCVR) having at least 95% sequence identity to SEQ ID NO:
18.
34. The antibody of claim 33, comprising a heavy chain (HC) having at least 95% sequence identity to SEQ ID NO:20 and a light chain (LC) having at least 95% sequence identity to SEQ ID NO:
22.
35. An antibody that binds to an epitope of XCL1 that includes one or more amino acids of SEQ ID NO:
27.
36. The antibody of claim 35, which binds to two or more amino acids of SEQ ID NO:
27.
37. The antibody of claim 36, which binds to three or more amino acids of SEQ ID NO:
27.
38. The antibody of claim 37, which binds to one or more amino acids of SEQ ID NO:
29.
39. An antibody that binds to an epitope of XCL1 that includes one or more amino acids of SEQ ID NO:
28.
40. The antibody of claim 39, which binds to two or more amino acids of SEQ ID NO:
28.
41. An antibody that binds to an epitope of XCL1 comprising one or more amino acids of SEQ ID NO:27 and one or more amino acids of SEQ ID NO:
28.
42. The antibody of claim 41, which binds to two or more amino acids of SEQ ID NO:27 and two or more amino acids of SEQ ID NO:
28.
43. The antibody of claim 41, which binds to one or more amino acids of SEQ ID NO:
29.
44. The antibody of any one of claims 1 to 43, wherein the antibody has a human IgG1 isotype.
45. A pharmaceutical composition comprising an antibody according to any one of claims 1 to 44 and one or more pharma- ceutically acceptable carriers, diluents, or excipients.
46. 46. A method of treating alopecia areata, vitiligo, asthma, psoriasis, multiple sclerosis, psoriasis, rheumatoid arthritis, or ulcerative colitis in a subject in need thereof, comprising administering to the subject an effective amount of an antibody according to any one of claims 1 to 44 or a pharmaceutical composition according to claim 45.
47. An antibody according to any one of claims 1 to 44 or a pharmaceutical composition according to claim 45 for use in therapy.
48. 46. The antibody of any one of claims 1 to 44 or the pharmaceutical composition of claim 45 for use in the treatment of alopecia areata, vitiligo, asthma, psoriasis, multiple sclerosis, rheumatoid arthritis, or ulcerative colitis.
49. Use of the antibody of any one of claims 1 to 44 or the pharmaceutical composition of claim 45 in the manufacture of a pharmaceutical agent for the treatment of alopecia areata, vitiligo, asthma, psoriasis, multiple sclerosis, rheumatoid arthritis, or ulcerative colitis.
50. A nucleic acid comprising a sequence encoding SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, or SEQ ID NO:
26.
51. A vector comprising a first nucleic acid sequence encoding SEQ ID NO:23 or SEQ ID NO:25 and a second nucleic acid sequence encoding SEQ ID NO:24 or SEQ ID NO:
26.
52. A cell comprising the vector of claim 51.
53. 53. A method of producing an antibody, comprising culturing the cell of claim 52 under conditions such that the antibody is expressed, and recovering the expressed antibody from the culture medium.
54. 53. An antibody produced by culturing the cell of claim 52 under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium.
55. A protein complex comprising dimeric XCL1 and an antibody bound to dimeric XCL1.
56. 56. The protein complex of claim 55, wherein the dimeric XCL1 is a homodimeric XCL1.
57. 57. The protein complex of claim 55 or 56, wherein the antibody binds to XCL1 in a β-sheet configuration.
58. A protein complex comprising dimeric XCL2 and an antibody bound to dimeric XCL2.
59. 59. The protein complex of claim 58, wherein the dimeric XCL2 is a homodimeric XCL2.
60. 60. The protein complex of claim 58 or 59, wherein the antibody binds to XCL2 in a β-sheet configuration.
61. A protein complex comprising: a heterodimer comprising a monomeric unit of XCL1 and a monomeric unit of XCL2; and an antibody bound to the heterodimer.
62. 62. The protein complex of claim 61, wherein the antibody binds to at least one amino acid residue of XCL1.
63. 63. The protein complex of claim 61 or 62, wherein the antibody binds to at least one amino acid residue of XCL2.
64. 64. The protein complex of any one of claims 61 to 63, wherein the antibody binds to at least one residue of XCL1 or XCL2 that is in a β-sheet configuration.
